Showing results (61-70 of 326) with videos related to
Sort By:
Pageof 33
Frontiers in Psychiatry|May 10, 2021
Availability of Illegal Drugs During the COVID-19 Pandemic in Western GermanyNorbert Scherbaum, Udo Bonnet, Henning Hafermann, et al.Journal of Clinical Psychopharmacology|April 14, 2022
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping ReviewUdo Bonnet, Georg JuckelCNS & Neurological Disorders Drug Targets|June 5, 2020
Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, Antimigraine and Neuroprotective PropertiesUdo Bonnet, Martin WiemannEuropean Archives of Psychiatry and Clinical Neuroscience|June 30, 2021
Do patients' resilience and subjective illness representation predict the outcome of a routine inpatient treatment program of major depressive disorder?Laura Marschollek, Udo BonnetFortschritte Der Neurologie-Psychiatrie|September 23, 2024
[The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update]Udo Bonnet, Georg JuckelProgress in Neuro-Psychopharmacology & Biological Psychiatry|April 8, 2006
A rare case of dependence on pemolineUdo Bonnet, Eugen DavidsBrain Sciences|October 29, 2025
Focus on 'Psychiatry and Addiction: A Multi-Faceted Issue'Fabrizio Schifano, Giovanni Martinotti, Norbert ScherbaumFrontiers in Psychiatry|June 20, 2022
Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification TreatmentMichael Specka, Thomas Kuhlmann, Udo Bonnet, et al.Psychiatrische Praxis|November 21, 2013
[Outcomes of comprehensive inpatient opiate detoxification in patients re-admitted to treatment within one year]Michael Specka, Kristina Lopez Gonzales, Norbert ScherbaumSubstance Abuse and Rehabilitation|May 12, 2017
The cannabis withdrawal syndrome: current insightsUdo Bonnet, Ulrich W PreussPageof 33